Tirzepatide vs Semaglutide: 20.9% vs 14.9% Weight Loss Compared

Tirzepatide and semaglutide are the two most-searched names in the GLP-1 category, and for good reason: they are the compounds behind the four brands most people have actually heard of, Mounjaro, Zepbound, Ozempic, and Wegovy. This comparison covers the trial numbers, including the rare direct head-to-head data, the mechanism, side effects, dosing, cost, and who each compound tends to fit.

This is written for research and educational purposes. It reports published trial data; it is not medical advice, and where these compounds are referenced as research materials rather than by brand, they are not approved for that use.

Tirzepatide vs semaglutide at a glance

The short version: tirzepatide has the higher number in both cross-trial and direct comparisons, and the extra GIP receptor is the leading explanation. The rest of this article is what sits behind each row.

Mounjaro, Zepbound, Ozempic, Wegovy: which name means what

Before the numbers make sense, the brand names need to be untangled, the same way "Ozempic vs Wegovy" confusion sits underneath most retatrutide comparisons.

Each row is one molecule sold under two labels for two indications. Semaglutide is Ozempic when the approved indication is type 2 diabetes and Wegovy when the indication is chronic weight management, at a higher titrated dose. Tirzepatide is Mounjaro for diabetes and Zepbound for weight management, again at the higher end of its titration range. So a search for "tirzepatide vs Ozempic" is really asking about tirzepatide vs semaglutide, and "Zepbound vs Wegovy" is really asking tirzepatide vs semaglutide at their respective weight-management doses. Everything below uses the molecule names, tirzepatide and semaglutide, since that is the actual comparison underneath every brand pairing.

The head-to-head numbers: SURMOUNT-1, STEP 1, and the direct trial

Most compound-versus-compound comparisons in this category rely on separate trials run years apart. This pair is unusual in that it also has genuine head-to-head data, trials that randomized the same population to one compound or the other.

The first four rows are cross-trial: SURMOUNT-1 and STEP 1 were separate studies with different populations, sites, and (slightly different) durations, so the 20.9% versus 14.9% gap is a strong signal rather than proof. ^{[1] [2]} The last row is different in kind. SURMOUNT-5 put people in the same trial and randomized them directly to tirzepatide (up to 15 mg) or semaglutide (up to 2.4 mg), and reported tirzepatide ahead by a comparable margin, roughly 20.2% versus 13.7% at 72 weeks. ^[4] That direct result is what makes this comparison more conclusive than most in the GLP-1 category, where cross-trial numbers are usually the best available evidence.

A second head-to-head trial, SURPASS-2, ran years earlier in people with type 2 diabetes rather than obesity, comparing tirzepatide's three doses against semaglutide 1 mg over 40 weeks. Tirzepatide outperformed semaglutide on both glycemic control and weight loss at every dose tested, with the gap widening at tirzepatide's higher doses. ^[3] Two separate head-to-head trials, run in different populations years apart, both point the same direction, which is a stronger evidence pattern than either result alone.

Why tirzepatide's number is bigger: dual vs single receptor mechanism

The efficacy gap traces to a mechanistic difference stated in one sentence: semaglutide activates one receptor; tirzepatide activates two.

Semaglutide is a pure GLP-1 agonist: it suppresses appetite, slows gastric emptying, and improves glucose handling through a single receptor, and that one lever is enough to reach 14.9% at its studied dose. ^[2] Tirzepatide keeps that same GLP-1 activity and adds a second receptor, GIP, glucose-dependent insulinotropic polypeptide. GIP does not appear to drive weight loss on its own; instead it seems to amplify what GLP-1 activation already does, a synergy rather than a second independent pathway. ^[5] That amplification is the leading mechanistic explanation for why the same class of drug reaches a higher ceiling with a second receptor engaged.

The practical upshot: semaglutide is the reference case for single-receptor GLP-1 activity, and tirzepatide is the demonstration that adding GIP raises the ceiling rather than simply adding a second, separate effect. The full receptor-level breakdown is in how peptides work: receptor mechanisms.

Side effects: how the profiles compare

Both compounds share the same dominant side-effect story, because both are built on GLP-1 receptor activation.

The gastrointestinal effects, nausea, diarrhea, constipation, and reduced appetite, are dose-dependent and concentrated during dose escalation in both compounds, then ease once the dose stabilizes. ^{[1] [2]} SURPASS-2's head-to-head design lets this be compared directly rather than across separate trials: it reported broadly similar overall rates of gastrointestinal adverse events between tirzepatide and semaglutide, with some measures trending slightly higher at tirzepatide's highest dose. ^[3] There is no dramatic difference in kind between the two, the shared mechanism produces a shared tolerability pattern, and the titration schedule in both programs exists to manage it.

Why both cause GI effects, and why they fade

The mechanism explains the timing. GLP-1 receptor activation slows gastric emptying, which is part of how both compounds reduce appetite, and that same slowing is what produces nausea when exposure changes too quickly. That is why symptoms are worst during dose escalation, when plasma levels are climbing fastest, and why they settle once the dose holds steady. Both trial protocols titrate stepwise over several weeks specifically to give the gut time to adapt at each level. ^{[1] [2]} None of this is dosing advice; it is the trial-reported rationale for why both escalation schedules look the way they do.

Dosing and titration: how the cadence differs

On the surface these two are close to identical to run: both are once-weekly subcutaneous compounds with multi-week stepwise titration. The differences are in the numbers.

Both cadences work because both molecules are engineered for a long half-life, semaglutide's roughly 7 days through fatty-acid albumin binding and protease resistance, and tirzepatide's roughly 5 days through a related long-acting design, both far beyond the minutes-long half-life of the native incretin hormones they are modeled on. ^[6] The practical consequence is the same for both: plasma levels build over weeks and reach steady state at roughly a month, which is exactly why trial endpoints are read at 68 and 72 weeks rather than early. A quiet first month is not a sign either compound is failing; it reflects levels still climbing toward steady state.

Cost and access: which is easier to get

Both molecules are FDA-approved, which changes the access conversation compared to an investigational compound like retatrutide, but they still diverge in practice.

Semaglutide, as Ozempic or Wegovy, has been on the market longer and has a broader manufacturing and pharmacy footprint, though both brands have experienced supply shortages at points since approval. Tirzepatide, as Mounjaro or Zepbound, is newer to market and has generally traded at a comparable or somewhat higher list price without insurance coverage. Both molecules also exist in the research-compound market at far lower prices than either branded product.

A "99% pure" figure is only meaningful if the other 1% is characterized. For research use, the impurity profile, meaning what the non-target fraction actually is, matters as much as the headline number, ideally confirmed by independent third-party testing rather than the manufacturer's numbers alone. What to look for when sourcing either compound is covered in what to look for when buying retatrutide, which applies the same evaluation framework across compounds.

Who each fits

Neither compound is universally the right choice. They sit at different points on an evidence-versus-simplicity curve.

Put plainly: tirzepatide carries the larger effect and the head-to-head wins; semaglutide carries the longer history and the simpler, single-receptor mechanism that made this entire drug class possible in the first place. For a research program built around peak studied effect, tirzepatide's numbers are the stronger draw. For a program anchored to the most extensively characterized single-receptor compound, semaglutide remains the reference.

If retatrutide is also in the comparison set, retatrutide vs tirzepatide and retatrutide vs semaglutide extend this same framework to the triple-agonist frontier compound.

The bottom line

On the numbers that matter most, tirzepatide leads, and unlike most comparisons in this category, that lead is confirmed by direct head-to-head trials rather than only cross-trial figures: 20.9% vs 14.9% in separate trials, and roughly 20.2% vs 13.7% when SURMOUNT-5 put both compounds in the same study. ^{[1] [2] [4]} Semaglutide's advantage is time in the field, the longer post-approval record behind Ozempic and Wegovy. The choice is less about which mechanism is valid and more about how much weight a larger, head-to-head-confirmed effect carries against a longer track record. For the full picture on each compound individually, see the complete tirzepatide guide and the complete semaglutide guide.

For research and educational purposes only. Not medical advice. Trial figures describe published clinical studies; cross-compound comparisons are drawn from separate trials except where a direct head-to-head trial (SURMOUNT-5, SURPASS-2) is specifically cited. Mounjaro, Zepbound, Ozempic, and Wegovy are FDA-approved prescription medications referenced here for comparison and brand clarity.